Head-to-head evidence
ACP-204 vs LY03017
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Serotonin 5-HT2A receptor (antagonist / inverse agonist) · full Alzheimer's Disease pipeline
ACP-204
Developed by Acadia Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2028 · NCT06159673 (registry estimate)
LY03017
Developed by Luye Pharma Group
NCT06388551 · Phase 1 · status unknown
This early-phase study randomly assigned healthy volunteers to ascending single oral doses of LY03017 or matching placebo under quadruple-blind conditions, tracking adverse events as the primary outcome. No results have been posted, so it remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-204's landscape · LY03017's landscape